2024 Top 10 Oncology Products Set New Sales Records

In 2024, the oncology drug market continues to hold a pivotal position within the global pharmaceutical industry, achieving record-breaking sales that reflect unprecedented growth potential. With advancements in precision medicine and immuno-oncology, innovative therapies such as targeted treatments and immune checkpoint inhibitors have seen remarkable commercial success worldwide. The leading cancer drugs are not only increasing in sales but are also driving technological innovation in cancer treatment, significantly benefiting numerous patients. By analyzing the top ten oncology products based on sales in 2024, we can explore how these drugs are shaping the future of cancer therapy and their importance to pharmaceutical companies and the healthcare system as a whole.

1. Keytruda (pembrolizumab)

   • Developer: Merck
   • Modality: Monoclonal Antibody
   • Mechanism: PD-1 Inhibitor
   • Launch Date: September 14, 2014
   • Indications: Melanoma, metastatic non-small cell lung cancer, and several others
   • Sales in 2024: $29.48 billion (18% increase)
   • Market Analysis: Keytruda continues to dominate the market with expanding indications. Its patent is set to expire in 2028, with peak sales expected by 2027.

2. Darzalex (daratumumab)

   • Developer: Johnson & Johnson / Genmab
   • Modality: Monoclonal Antibody
   • Mechanism: Anti-CD38 Antibody
   • Launch Date: November 16, 2015
   • Indications: Multiple Myeloma
   • Sales in 2024: $11.67 billion (20% increase)
   • Market Analysis: Darzalex significantly improves survival rates in multiple myeloma patients, maintaining strong growth momentum.

3. Opdivo

   • Developer: Bristol-Myers Squibb
   • Modality: Monoclonal Antibody
   • Mechanism: PD-1 Inhibitor
   • Launch Date: December 22, 2014
   • Indications: Melanoma, lung cancer, and others
   • Sales in 2024: $9.304 billion (7% increase)
   • Market Analysis: Opdivo is actively pursuing additional opportunities, including new trials for various cancers.

4. Tagrisso (osimertinib)

   • Developer: AstraZeneca
   • Modality: Small Molecule
   • Mechanism: EGFR Tyrosine Kinase Inhibitor
   • Launch Date: November 13, 2015
   • Indications: Non-small cell lung cancer
   • Sales in 2024: $6.58 billion (12% increase)
   • Market Analysis: Tagrisso shows significant clinical efficacy for EGFR-mutated non-small cell lung cancer.

5. Imbruvica (ibrutinib)

   • Developer: Johnson & Johnson / AbbVie
   • Modality: Small Molecule
   • Mechanism: BTK Inhibitor
   • Launch Date: November 13, 2013
   • Indications: Chronic Lymphocytic Leukemia
   • Sales in 2024: $3.347 billion (6.9% decrease)
   • Market Analysis: Despite a drop in sales, Imbruvica remains a crucial asset for AbbVie.

6. Xtandi (enzalutamide)

   • Developer: Pfizer / Astellas
   • Modality: Small Molecule
   • Mechanism: Androgen Receptor Inhibitor
   • Launch Date: August 31, 2012
   • Indications: Prostate Cancer
   • Sales in 2024: $2.04 billion (23% increase)
   • Market Analysis: Xtandi continues to gain traction in various stages of prostate cancer treatment.

7. Revlimid (lenalidomide)

   • Developer: Bristol-Myers Squibb
   • Modality: Small Molecule
   • Mechanism: Immunomodulator
   • Launch Date: December 27, 2005
   • Indications: Multiple Myeloma
   • Sales in 2024: $5.773 billion (5% decrease)
   • Market Analysis: Revlimid’s market share has been impacted by generic competition after patent expiration.

8. Verzenio (abemaciclib)

   • Developer: Eli Lilly
   • Modality: Small Molecule
   • Mechanism: CDK4/6 Inhibitor
   • Launch Date: September 28, 2017
   • Indications: Breast Cancer
   • Sales in 2024: $5.307 billion (37% increase)
   • Market Analysis: Verzenio effectively inhibits tumor cell proliferation, showing remarkable efficacy in HR+ HER2- breast cancer.

9. Lynparza (olaparib)

   • Developer: AstraZeneca / Merck
   • Modality: Small Molecule
   • Mechanism: PARP Inhibitor
   • Launch Date: December 19, 2014
   • Indications: Ovarian Cancer
   • Sales in 2024: $3.672 billion (7% increase for AstraZeneca)
   • Market Analysis: Lynparza continues to expand its indications, providing a significant market opportunity.

10. Imfinzi (durvalumab)

    • Developer: AstraZeneca
    • Modality: Monoclonal Antibody
    • Mechanism: PD-L1 Inhibitor
    • Launch Date: May 1, 2017
    • Indications: Lung Cancer
    • Sales in 2024: $4.717 billion (9% increase)
    • Market Analysis: Imfinzi is gaining traction due to its expanding range of approved indications.

While small molecules have a slight advantage in numbers among the top ten products, the leading three are monoclonal antibodies, with sales figures nearing or exceeding $10 billion. In total, small molecules achieved sales of $35.1 billion, while monoclonal antibodies reached $55.2 billion.

From an indication perspective, most of the top ten products target solid tumors (seven), while three focus on blood cancers, highlighting significant unmet needs and development potential in the hematologic oncology market. The future may see more cell and gene therapies entering this field, playing an increasingly important role.